title: Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient.
abstract: During the last decades, the introduction of new cytotoxics and targeted therapies resulted in a prolongation of survival and a minimization of toxicity in the treatment of metastatic breast cancer. However, to date, there was no standard of care following second-line therapy in this setting. In Phase III EMBRACE study, eribulin obtained a statistically significant improvement in the overall survival of pretreated metastatic breast cancer patients. This case report describes a heavily chemo-pretreated woman with important bone, nodal, hepatic and choroidal involvement from breast cancer who had a remarkable, unexpected and lasting disease response after treatment with eribulin. This case underlines how this well-tolerated monochemotherapy may be able to obtain a prolonged disease control and a good clinical outcome.
authors.affiliation: Medical Oncology Unit, AO Papardo-Department of Human Pathology, University of Messina, Messina, Italy.
authors.forename: Giuseppina Rosaria Rita
authors.initials: GR
authors.lastname: Ricciardi
authors.forename: Claudia
authors.initials: C
authors.lastname: Proto
authors.forename: Giuseppa
authors.initials: G
authors.lastname: Ferraro
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Adamo
mesh_terms: D050256:Antimitotic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D005134:Eye Neoplasms / Q000175:diagnosis* / Q000556:secondary; D005260:Female; D005663:Furans / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000627:therapeutic use*; D008875:Middle Aged; D016896:Treatment Outcome; D000095662:Polyether Polyketides
chemical_list: D050256:Antimitotic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides
keywords: eribulin; heavily pretreated patient; metastatic breast cancer